NCT04568265View on ClinicalTrials.gov

A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B

PHASE2RecruitingINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

June 3, 2020

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2025

Conditions
Hepatitis BChronic Hep BHBV
Interventions
DRUG

APG-1387

Weekly intravenous infusion for 30 minutes

DRUG

Entecavir 0.5 mg

Taken daily by mouth

Trial Locations (4)

Unknown

RECRUITING

Guangzhou Eighth People's Hospital, Guangzhou

RECRUITING

Nanfang Hospital of Southern Medical University, Guangzhou

NOT_YET_RECRUITING

Huashan Hospital affiliated to Fudan University, Shanghai

NOT_YET_RECRUITING

West China Hospital, Sichuan University, Chengdu

Sponsors
All Listed Sponsors
lead

Ascentage Pharma Group Inc.

INDUSTRY

NCT04568265 - A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B | Biotech Hunter | Biotech Hunter